Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer

By Tecimer C.   Doering D.L.   Goldsmith L.J.   Meyer J.S.   Abdulhay G.   Wittliff J.L.  

Gynecologic Oncology, Vol. 80, Iss. 1, 2001-01 ,pp. : 48-55

Elsevier

Access to resources Recommend Favorite

Celecoxib Inhibits Urokinase-Type Plasminogen Activator (uPA) Production in MDA-MB-231 Breast Cancer Cells

By Andrews Heather   Habibi Golerah   Kucab Jill   Dunn Sandra  

Breast Cancer Research and Treatment, Vol. 94, Iss. 1, 2005-11 ,pp. : 47-52

Springer Publishing Company

Access to resources Recommend Favorite

Inhibition of Human Breast Cancer Cell Invasion by siRNA Against Urokinase-Type Plasminogen Activator

By Huang Hong-Yan   Jiang Ze-Fei   Li Qing-Xia   Liu Jia-Yun   Wang Tao   Zhang Rui   Zhao Jing   Xu Yan-Ming   Bao Wei   Zhang Yong   Jia Lin-Tao   Yang An-Gang  

Cancer Investigation, Vol. 28, Iss. 7, 2010-07 ,pp. : 689-697

Informa Healthcare

Access to resources Recommend Favorite

The p75^NTR metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells

By Nalbandian Angèle   Djakiew Daniel  

Clinical and Experimental Metastasis, Vol. 23, Iss. 2, 2006-04 ,pp. : 107-116

Springer Publishing Company

Access to resources Recommend Favorite